Literature DB >> 11535337

Bordetella bronchiseptica fimbrial protein-enhanced immunogenicity of a Mannheimia haemolytica leukotoxin fragment.

S Rajeev1, S A Kania, R V Nair, J T McPherson, R N Moore, D A Bemis.   

Abstract

Leukotoxin produced by Mannheimia (Pasteurella) haemolytica is an important virulence factor in shipping fever pneumonia in feedlot cattle and is a critical protective antigen. In this study, the immune response to a chimeric protein generated by combining a gene fragment encoding neutralizing epitopes of M. haemolytica leukotoxin and a fimbrial protein gene (fim N) from Bordetella bronchiseptica was evaluated. The recombinant gene was cloned in a bacterial expression vector under the control of the tac promoter and expressed as a fusion protein with glutathione-S-transferase (GST) in Escherichia coli. Immunization of mice with the recombinant protein, GST-LTXFIM elicited a significantly stronger anti-leukotoxin antibody response than comparable immunizations with GST-LTX fusion proteins lacking FIM N. The GST-LTXFIM was also more stable than GST-LTX during storage at -80 degrees C, thus alleviating a stability problem inherent to leukotoxin. This chimeric protein may be a candidate for inclusion in new generation vaccines against shipping fever pneumonia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535337     DOI: 10.1016/s0264-410x(01)00226-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Characterization of immunodominant and potentially protective epitopes of Mannheimia haemolytica serotype 1 outer membrane lipoprotein PlpE.

Authors:  Sahlu Ayalew; Anthony W Confer; Emily R Blackwood
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

2.  Immunization with recombinant PlpE of ovine Mannheimia haemolytica isolate provides protection against lethal challenge in mice.

Authors:  A Yektaseresht; Z Hemati; F Sabet Sarvestani; A Hosseini; S Vir Singh
Journal:  Iran J Vet Res       Date:  2021       Impact factor: 1.376

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.